Key result
ELABELA pretreatment boosts mesenchymal stem cell homing and improves post-infarct LVEF in preclinical models.
Why the study?
It is unclear whether mesenchymal stem cell transplantation enhances nerve growth factor secretion and affects cardiac sympathetic remodeling after myocardial infarction.
Answers are grounded in this paper and cite their sources.
BACKGROUND: Transplantation of mesenchymal stem cells (MSCs) alters the ventricular electrophysiologic properties after myocardial infarction (MI) in rats. However, it is unclear whether MSCs transplantation enhances the secretion of nerve growth factor (NGF) and affects cardiac sympathetic remodeling. METHODS: MI was induced in 35 male Sprague-Dawley rats. Two weeks later, the animals were randomized to MSCs or phosphate buffer solution (PBS) injections into the infarcted myocardium. Six weeks thereafter, the expressions of NGF, growth associated protein 43 (GAP43) and tyrosine hydroxylase (TH) were measured and the density of GAP43 and TH positive nerves was calculated in the borderzone. NGF levels were detected in different culture conditions with neonatal rat ventricular myocytes (NRVMs, 2 × 10(5)/well) and MSCs (2 × 10(5)/well). RESULTS: Compared with PBS, mRNA expression and protein levels of NGF, GAP43 and TH increased in the border zone after MSCs injection. Immunohistochemistry showed more GAP43- and TH-positive nerves in the MSCs than in the PBS group. Compared to monocultured MSCs, mono-cultured NRVMs secreted more NGF in vitro. CONCLUSIONS: The expression of NGF increased after MSCs transplantation, which may affect sympathetic remodeling and the electrophysiological properties after MI. Paracrine factors secreted by MSC-CM may be involved in this process.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2014) studied Myocardial infarction/reperfusion injury (n=32). ELABELA-pretreated bone marrow mesenchymal stem cells (BMSCs) vs. Vehicle (PBS) or un-pretreated BMSCs was evaluated on Myocardial repair and cardiac function (LVEF and LVFS) (p=<0.05). Pretreatment of bone marrow mesenchymal stem cells with ELABELA significantly enhanced their migration and homing to the injured myocardium, leading to improved left ventricular function and reduced fibrosis compared to untreated cells in a rat model.
Synapse has enriched 10 related papers. Consider them for comparative context: